The SYNCHRONIZE-MASLD trial, the largest controlled study of its kind, reveals significant therapeutic potential for survodutide in treating metabolic dysfunction-associated steatotic liver disease. The phase 3 randomized, double-blind trial enrolled 730 adults with obesity and confirmed MASLD, comparing weekly subcutaneous survodutide injections to placebo over 48 weeks.
Survodutide’s innovative dual-hormone mechanism activates both glucagon and GLP-1 receptors, simultaneously promoting hepatic fat breakdown and regulating appetite control—a departure from existing single-pathway therapies. Results published in Nature Medicine demonstrate substantial clinical benefit, positioning this approach as a landmark intervention for patients with obesity and fatty liver disease.
These findings support ongoing regulatory pathways, with potential market availability anticipated in 2027, offering clinicians a novel therapeutic option for a previously difficult-to-treat condition.
Read the full article on GMJ Newsroom.
Was this article helpful?
